Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk FY24 Results | Contract Pharma

What are you searching for?

Sign in
Financial News

Novo Nordisk FY24 Results

Diabetes and Obesity care increased by 26%, driven by GLP-1 diabetes sales growth of 21% and Obesity care growing by 56%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: Novo Nordisk

Novo Nordisk

FY Revenues: $40.6 billion (+25%)

FY Earnings: $14.1 billion (+21%)

Comments: Sales in North America Operations increased by 30% in Danish kroner. Sales in International Operations increased by 17% in Danish kroner.

Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion, mainly driven by GLP-1 diabetes sales growth of 21% in Danish kroner and Obesity care growing by 56% in Danish kroner to DKK 65.1 billion. Rare disease sales increased by 9% in Danish kroner.

In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics